Company / SG&A Expense
Corvus Pharmaceuticals, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.2M
FY2024
5-year range
$6.9M / $11.9M
FY2020-FY2024
Trend
+18.6%
vs FY2023
Sector context
#208 of 211
Health Care
What the data says
Among 211 Health Care companies, Corvus Pharmaceuticals, Inc. is in the top 1% for sg&a expense. SG&A Expense returned to growth in FY2024 after 3 years of decline, reaching $8M.
Based on SEC 10-K filings.
$8M in FY2024 with a 5-year CAGR of -5.6%.
Remained stable around $8M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -5.0%
- 5-Year CAGR
- -5.6%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 211This company $8.2M Sector average $728.7M
▼
-98.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.6%, indicating a declining trend.
- In FY2024, sg&a expense increased 18.6% year-over-year.
- Ranks #208 out of 211 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.2M | +18.6% |
| FY2023 | $6.9M | -15.0% |
| FY2022 | $8.1M | -14.9% |
| FY2021 | $9.5M | -20.2% |
| FY2020 | $11.9M | +9.7% |
| FY2019 | $10.9M | +2.3% |
| FY2018 | $10.6M | +4.1% |
| FY2017 | $10.2M | +34.1% |
| FY2016 | $7.6M | +215.1% |
| FY2015 | $2.4M | +1865.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026